Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Tenet Healthcare (THC), Revvity (RVTY) and Biogen (BIIB)

Tipranks - Tipranks - Wed Feb 4, 7:46AM CST

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Tenet Healthcare (THC – Research Report), Revvity (RVTY – Research Report) and Biogen (BIIB – Research Report).

Claim 50% Off TipRanks Premium

Tenet Healthcare (THC)

Morgan Stanley analyst Craig Hettenbach maintained a Buy rating on Tenet Healthcare today and set a price target of $247.00. The company’s shares closed last Monday at $188.03.

Hettenbach has an average return of 18.8% when recommending Tenet Healthcare. ;'>

According to TipRanks.com, Hettenbach is ranked #3130 out of 12040 analysts.

Tenet Healthcare has an analyst consensus of Strong Buy, with a price target consensus of $242.89, representing a 28.0% upside. In a report issued on January 22, RBC Capital also maintained a Buy rating on the stock with a $252.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Revvity (RVTY)

Stifel Nicolaus analyst Daniel Arias maintained a Hold rating on Revvity today and set a price target of $110.00. The company’s shares closed last Monday at $107.09.

According to TipRanks.com, Arias is a 3-star analyst with an average return of 2.2% and a 48.8% success rate. Arias covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, BillionToOne, Inc. Class A, and Tempus AI, Inc. Class A. ;'>

Revvity has an analyst consensus of Moderate Buy, with a price target consensus of $110.67, implying a 5.9% upside from current levels. In a report released yesterday, TipRanks – Google also downgraded the stock to Hold with a $116.00 price target.

Biogen (BIIB)

RBC Capital analyst Brian Abrahams maintained a Buy rating on Biogen today and set a price target of $217.00. The company’s shares closed last Monday at $179.09.

According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 6.0% and a 48.7% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, MoonLake Immunotherapeutics, and Aardvark Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $190.74 average price target, representing a 6.4% upside. In a report issued on January 30, Oppenheimer also maintained a Buy rating on the stock with a $225.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).